Behind The NASH Leaders, Pursuers Already Anticipating Second-Wave Improvements
Privately held Cirius and NGM and big pharma Bristol-Myers Squibb are in Phase II for NASH with programs also working to validate non-invasive biomarkers for diagnosis, prognosis and treatment impact.
You may also be interested in...
While the proposed Bristol/Celgene merger nears an April vote, Celgene continues a recent spate of deal-making, paying $25m up front to Exscientia to discover small molecule candidates for cancer and autoimmune disease.
Along with last week's acquisition of three NASH candidates from Lilly by Terns, NASH remains a heavily crowded R&D space as the European Association for the Study of the Liver annual meeting approaches.
In a video interview at the Biotech Showcase, Cirius CEO Bob Baltera explains his company's approach to NASH and looks forward to milestones ahead for its insulin-sensitizing lead candidate MSDC-0602K.